Blend Formulation & Dispensing Record (Essential Oils)

Blend Formulation & Dispensing Record

Header & Metadata

Patient: [Name, DOB, MRN] (Required—do not finalize record if any identifier is missing)

Encounter/Order ID: [Identifier] (Required)

Preparation/Batch ID: [Unique ID] (Required—assign unique ID even for single-patient blends)

Date Formulated: [YYYY-MM-DD] (Required)

Date Prepared: [YYYY-MM-DD] (Required if compounded on-site; omit if dispensing commercial product)

Date Dispensed: [YYYY-MM-DD] (Required)

Formulator: [Name, credentials] (Required)

Preparer: [Name, credentials] (Required if compounded on-site)

Verifier: [Name, credentials] (If second check not performed, enter "Single-person workflow per policy")

Clinical Context

Indication/Goal: [Clinical objective or symptom target] (Link to diagnosis/problem if applicable; if indication not documented here, enter "See linked encounter note for clinical reasoning")

Route: [topical / inhalation / bath / compress] (If topical, include statement: "External use only")

Application Site: [Intended site(s) and areas to avoid]

Duration: [Start date, stop date or trial period, PRN parameters if applicable]

Safety Screening

(For each item, document [Yes / No / Not assessed]. Treat "Not assessed" as requiring follow-up unless encounter setting prevents assessment.)

• Allergies/sensitivities to essential oils, fragrances, botanical families, or carrier oils (specify if nut-derived): [Yes / No / Not assessed] [Details if Yes]
• Skin conditions relevant to topical use (eczema, contact dermatitis history, broken skin at application site): [Yes / No / Not assessed] [Details if Yes]
• Respiratory risk factors for inhalation (asthma, fragrance-triggered symptoms): [Yes / No / Not assessed] [Details if Yes]
• Pregnancy or breastfeeding: [Yes / No / Not assessed]
• Pediatric or geriatric considerations; supervision requirements: [Yes / No / Not assessed] [Details if applicable]

Relevant comorbidities/medications that materially alter risk: [Comorbidities or medications affecting safety, e.g., anticoagulation with salicylate-containing products] (If none, document "None reported" or "Not assessed—follow-up required")

Product Specification

Preparation Name: [Patient-facing name; internal standardized name if different]

Dosage Form: [roll-on / massage oil / inhaler / spray / balm / other]

Total Quantity: [Volume or mass with container count, e.g., "10 mL roll-on × 1"] (Required)

Total Essential Oil Concentration: [Percentage, w/w or v/v] (Required—do not finalize if blank)

Carrier/Base: [Identity and grade, e.g., fractionated coconut oil, jojoba] (If undiluted, enter "100% essential oil (undiluted)—rationale documented")

Ingredient Table

(One row per component. Record only information from supplier documentation—do not infer. If unavailable, document "Not provided by supplier." If lot tracking not performed, state "Lot tracking not performed per clinic workflow" rather than leaving fields blank.)

Ingredient	Type	Botanical Name & Plant Part	Extraction Method	Supplier	Lot/Batch Number	Expiration Date	Quantity Used	Concentration in Final Product	Notes
[Common name]	[essential oil / carrier oil / excipient]	[Botanical name, plant part]	[steam-distilled / expressed / CO₂ / other]	[Supplier name]	[Lot number]	[Expiration or date received/opened]	[Mass or volume]	[% or mg/mL]	[Allergens, photoreactivity, irritants]
[Common name]	[Type]	[Botanical name, plant part]	[Extraction method]	[Supplier name]	[Lot number]	[Expiration or date received/opened]	[Quantity]	[% or mg/mL]	[Notes]

Dilution Verification

Target Concentration: [Value and basis, e.g., 2% w/w] (Required)

Calculation Method: [w/w / v/v] (If v/v, note density assumptions)

Verification: [pass / fail] (If quantities missing, enter "Unable to verify dilution")

Verified By: [Initials and date] (If single-person workflow, enter "Single-person workflow per policy")

Preparation Notes

(Include only if compounded on-site. Omit section entirely for commercial or patient-supplied products.)

Master Formula Reference: [Formula ID or "patient-specific formulation"]

Patient-Specific Modifications: [Modifications and rationale]

Process Summary: [Key steps, order of mixing, equipment used for traceability]

Deviations/Variances: [Description and disposition] (If none, enter "None")

Quality Checks and Release

• Visual inspection (clarity, phase separation, particulate, container integrity): [pass / fail] [Notes]
• Volume/weight matches intended amount: [pass / fail] [Measured value]
• Label matches formulation record and route: [pass / fail]

Release Decision: [released / quarantined / discarded] [Reason if not released]

Released By: [Preparer name/date; Verifier name/date] (Or "Single-person release per policy")

Packaging and Label

Container: [Type and material, e.g., amber glass roll-on]

Closure: [child-resistant / tamper-evident / standard]

Fill Amount: [Measured volume or mass]

Label Elements (record copy):

• Patient name: [Name]
• Preparation name: [Name]
• Essential oil listing: [individual oils listed / "essential oil blend—see ingredient list"]
• Concentration: [Total EO %, w/w or v/v]
• Route and directions: [Route with brief application instructions]
• Storage: [Storage instructions]
• Beyond-use date and date prepared: [BUD; Date prepared]
• Preparation/lot ID: [ID]
• Clinic name and contact: [Clinic information]

Applied Warnings: [Select all that apply: external use only; avoid eyes and mucous membranes; do not apply to broken skin; discontinue if rash, swelling, or respiratory irritation occurs; keep out of reach of children and pets; avoid sun/UV exposure for specified hours (if photoreactive oils present); patch test recommended; do not ingest]

Beyond-Use Date Basis: [default per policy / limited by earliest component expiration / stability reference]

Dispensing and Counseling

Quantity Dispensed: [Amount]

Containers Dispensed: [Count and sizes]

Dispensed By: [Name, credentials, date/time]

Method: [in-person pickup / mailed / other]

Recipient: [patient / authorized person with name and relationship]

Counseling Documented: [Topics covered: application technique, frequency, adverse effect signs, storage, photoreactivity precautions, ingestion avoidance, child/pet safety] (For refills without formulation change: "Reviewed continued safe use; no new contraindications")

Handouts Provided: [yes / no] [Title if yes]

Consent/Acknowledgment: [Method and date] (If clinic uses integrative therapy consent)

Patient Understanding Confirmed: [teach-back / brief assessment / other method]

Monitoring and Follow-up

Reassessment Timing: [Timeframe, e.g., 2–4 weeks]

Stop Criteria: [Criteria, e.g., rash, worsening symptoms, respiratory irritation]

Adverse Event Documentation: [Description, onset, severity, suspected ingredient, action taken, lot flagged for review] (Complete only if adverse event occurs)